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Adhesion receptors, such as CD44, have been shown to activate receptor interacting
protein kinase-3 (RIPK3)—mixed lineage kinase-like (MLKL) signaling, leading to a non-
apoptotic cell death in human granulocyte/macrophage colony-stimulating factor (GM-
CSF) – primed neutrophils. The signaling events of this necroptotic pathway, however,
remain to be investigated. In the present study, we report the design, synthesis, and
characterization of a series of novel serine protease inhibitors. Two of these inhibitors,
compounds 1 and 3, were able to block CD44-triggered necroptosis in GM-CSF-primed
neutrophils. Both inhibitors prevented the activation of MLKL, p38 mitogen-activated
protein kinase (MAPK) and phosphatidylinositol 3’—kinase (PI3K), hence blocking the
increased levels of reactive oxygen species (ROS) required for cell death. Although
compounds one and three partially inhibited isolated human neutrophil elastase (HNE)
activity, we obtained no pharmacological evidence that HNE is involved in the initiation of
this death pathway within a cellular context. Interestingly, neither serine protease inhibitor
had any effect on FAS receptor-mediated apoptosis. Taken together, these results
suggest that a serine protease is involved in non-apoptotic CD44-triggered RIPK3-
MLKL-dependent neutrophil cell death, but not FAS receptor-mediated caspase-
dependent apoptosis. Thus, a pharmacological block on serine proteases might be
beneficial for preventing exacerbation of disease in neutrophilic inflammatory responses.
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INTRODUCTION
Neutrophils are the most abundant leukocytes in human blood
and play an essential role in innate immunity (Simon, 2003;
Nauseef and Borregaard, 2014; Wang et al., 2018). Caspase-
dependent apoptosis represents the most common form of
both physiological and pathological cell death in neutrophils
(Simon, 2003; Conus et al., 2008; Geering and Simon, 2011).
In the resolution of inflammation, neutrophils rapidly undergo
apoptosis and are removed by other phagocytic cells. Therefore,
neutrophil apoptosis is considered to be an option for limiting
tissue damage by preventing the release of histotoxic contents
from dying cells (Simon, 2003; Geering and Simon, 2011).
However, other types of neutrophil death have also been
reported, for example necroptosis (Wang et al., 2016; Barbosa
et al., 2018; Nakazawa et al., 2018; Wang et al., 2018; Zhou et al.,
2018). Neutrophil necroptosis is a regulated form of necrosis,
which is dependent on receptor interacting protein kinase-3
(RIPK3) and mixed lineage kinase-like (MLKL) activities
(Wang et al., 2018). At the inflammatory sites, when
neutrophils are activated by cytokines and other inflammatory
mediators, as well as through adhesion receptors, neutrophil
necroptosis can be triggered, most likely causing host tissue
damage (Wang et al., 2018). Thus, necroptotic neutrophils are
considered highly detrimental for the resolution of inflammation
owing to the consequent release of toxic cellular contents and the
potential escape of pathogens into the surroundings (Geering
et al., 2013; Wang et al., 2018).
The mode of cell death has consequences for the surrounding
environment and inflammatory responses. This is especially
relevant for neutrophils, which contain granules filled with
reactive chemicals and enzymes (Cowland and Borregaard,
2016; Benarafa and Simon, 2017). Clearly, a necrotic
neutrophil may induce inflammatory responses by the
immediate release of danger-associated molecular patterns
(DAMPs), but also by causing tissue damage (Geering et al.,
2013; Wang et al., 2018). Therefore, understanding the molecular
mechanisms of non-apoptotic neutrophil death pathways may
provide specific targets for potential therapeutic intervention in
infectious, inflammatory and autoimmune diseases. Non-
apoptotic neutrophil death pathways can be triggered in
cytokine-primed neutrophils by ligation of surface receptors
such as CD44 (Mihalache et al., 2011; Wang et al., 2016),
CD11b (Wang et al., 2016), CD18 (Wang et al., 2016), CD15
(Wang et al., 2016), Siglec-9 (von Gunten et al., 2005), or CD89
(Wehrli et al., 2014).
Using a pharmacological approach, the activation of the
RIPK3—MLKL signaling pathway has been shown to be
essential for human neutrophils to undergo such a non-
apoptotic cell death, suggesting that this type of death uses
elements of the necroptotic pathway (Wang et al., 2016).
Serine proteases constitute almost one third of all proteases
(Hedstrom, 2002), and probably they are the enzymes that have
been most studied in details (Page and Di Cera, 2008; Soualmia
and El Amri, 2018). Serine proteases are characterized by a
catalytic serine residue at the active site and have been shown
to play essential roles in biological processes in blood coagulation,
development, cell death, inflammation, immune response, and
signal transduction (Heutinck et al., 2010; Turk et al., 2012;
Benarafa and Simon, 2017; Soualmia and El Amri, 2018). In
the present report, we have investigated the effect of novel, newly
synthesized serine protease inhibitors on neutrophil death
in vitro. Two inhibitors, designated here as compounds 1 and
3, were shown to be able to inhibit CD44-induced necroptotic cell
death in granulocyte/macrophage colony-stimulating factor
(GM-CSF)-primed human neutrophils. In contrast, FAS
receptor-mediated neutrophil apoptosis was not blocked.
Interestingly, both compounds 1 and 3 inhibited MLKL, p38,
PI3K and NADPH oxidase activation. Moreover, similar to
compounds 1 and 3, N-p-tosyl-L-phenylalanine chloromethyl
ketone (TPCK) blocked the same signaling events leading to
neutrophil death. Taken together, these results suggest that serine
protease activity is required to activate MLKL in neutrophils,
leading to high ROS production and subsequent non-apoptotic
cell death.
MATERIALS AND METHODS
Design and Synthesis of the Compounds
A group of structurally related hydrazide or sulfonohydrazide
derivatives was chosen for current study. The design, synthesis
and spectroscopic data of compounds 2, 5–14 (structures
presented in Supplementary Table S1) have been previously
described (Obreza et al., 2004a; Obreza et al., 2004b; Smolnikar
et al., 2007). All chemicals were obtained from commercial
sources (Carlo Erba, Acros Organics, Emsure, TCI, AK
Scientific, Sigma Aldrich, Merck and Fluka) and were used
without further purification. Analytical thin-layer
chromatography (TLC) was performed on Merck silica gel
(60F254) plates (0.25 mm). Column chromatography was
performed on silica gel 60 (Merck, particle size
0.040–0.063 mm). Melting points were determined on a
Reichert hot stage microscope and are uncorrected. 1H– and
13C–NMR spectra were recorded on a Bruker AVANCE DPX400
spectrometer in CDCl3 or DMSO–d6 solution with TMS as
internal standard. Chemical shifts are reported in ppm (δ)
downfield from TMS. All the coupling constants (J) are in
hertz. IR spectra were recorded on a PerkinElmer Spectrum
BX System FT–IR spectrometer. Mass spectra were measured
with Advion expression CMLS mass spectrometer with ESI
ionization. High-performance mass spectra were obtained with
a Exactive™ Plus Orbitrap Mass Spectrometer with ESI
ionization. Reported yields are of purified products.
Compounds 1 were synthesized according to the modified
procedure in which 4-aminopiperidine was used instead of
azetidine (Obreza et al., 2004a). Compound 3 was prepared in
a three step synthesis from corresponding aldehyde and
hydrazide. Cyanobenzaldehyde (1.31 g; 10.0 mmol) and 2-
naphthohydrazide (1.86 g; 10.0 mmol) were dispersed in
20 ml of anhydrous ethanol and refluxed for 5 h.
Approximately 50% of the solvent was then removed in
vacuo and the residue diluted with water. The resulting
white solid was filtered and dried.
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N′-(4-cyanobenzylidene)-2-naphthohydrazide (2.06 g;
6.89 mmol) was dissolved in 25 ml of methanol. 200 mg of
10% palladium on activated charcoal was added to the
solution with constant influx of argon. The reaction mixture
was hydrogenated overnight at 2 bar for 3 h at room temperature.
After the catalyst was removed, the solvent was evaporated under
reduced pressure.
N′-(4-cyanobenzyl)-2-naphthohydrazide (1.50 g; 4.98 mmol)
was dissolved in anhydrous ethanol. Hydroxylamine
hydrochloride (402 mg; 5.78 mmol) and K2CO3 (1.30 g;
9.42 mmol) were added and the mixture was stirred for 6 h at
59 °C. The solvent was removed in vacuo and the residue
dissolved in mixture of ethyl acetate (30 ml) and water
(20 ml). Phases were separated and organic phase washed with
10% citric acid (20 ml), concentrated NaHCO3 (20 ml) and brine
(20 ml), dried over sodium sulfate and the solvent removed in
vacuo. The crude product was re-crystallized from ethanol.
The characterization of the compounds by spectroscopy and
enzyme kinetics are described in the Supplementary Material.
Reagents and Antibodies
Anti-CD44 mAb (clone A3D8), GW311616A,
dihydrorhodamine 123 (DHR), the cell permeable inhibitor of
human leukocyte elastase, N-(methoxysuccinyl)-alanyl-alanyl-
prolyl-valyl-chloromethyl ketone (AAPVCK), and the elastase
inhibitor IV were from Sigma-Aldrich (Buchs, Switzerland). The
F(ab’)2 fragments of the secondary goat anti-mouse (GaM) Ab
was purchased from Jackson ImmunoResearch Laboratories
(Milan Analytica; Roche Diagnostics, Rotkreuz, Switzerland).
GM-CSF was supplied by Novartis Pharma (Nürnberg,
Germany). Wortmannin and diphenylene iodonium (DPI)
chloride were purchased from Calbiochem Novabiochem (La
Jolla, CA, United States). Q-VD-Oph was from SM
Biochemicals (Anaheim, California, United States). PD169316
was obtained from Merck Millipore (Darmstadt, Deutschland).
Anti-FAS agonistic mAb (CH11) was purchased from MBL
International (Woburn, MA, United States). GSK′872 was
from Glixx Laboratories (Southborough, MA) and
GW806742X was from Adipogen AG (Liestal, Switzerland).
Rabbit anti-MLKL and rabbit anti-phospho-MLKL (phospho
Ser358) mAb were from Abcam (Cambridge,
United Kingdom). Rabbit anti-caspase-3, rabbit anti-AKT,
rabbit anti-phospho-Ser473-AKT, rabbit anti-p38, and rabbit
anti–phospho-Thr180/Tyr182-p38 were all from Cell Signaling
Technology (Danvers, MA, United States). Anti-GAPDH mAb
was obtained from Chemicon International (Chandlers Ford,
United Kingdom). HRP-coupled secondary Abs (anti-mouse
IgG and anti-rabbit IgG) were from GE Healthcare (VWR,
Switzerland). Luminata™ Forte Western HRP substrate was
purchased from Millipore Corporation (Billerica, MA,
United States). The monovalent Smac mimetic compound AT-
406 was from Selleckchem (Houston, TX, United States). Human
TNF-α was purchased from R and D Systems (Abingdon,
United Kingdom). Abz-APEEIMRRQ-EDDnp was from
PeptaNova GmbH (Sandhausen, Germany). White
polypropylene-well, 96-well microplates (Hard-Shell Thin-Wall
Microplates, cat. no. Hardshell microplaques 96 black shell, white
wells, # 80050379) were from Bio-Rad Laboratories (Hercules,
CA94547, United States).
Cells
Peripheral blood neutrophils were purified from healthy normal
individuals by Ficoll-Hypaque centrifugation, as described
previously (Mihalache et al., 2011; von Gunten et al., 2005;
Wang et al., 2016; Stojkov et al., 2017). The purity of the
isolated human neutrophil populations was always >95%, as
assessed by staining with Diff-Quik (Baxter, Düdingen,
Switzerland) and light microscopic analysis. Caspase-8-
deficient Jurkat cells were a kind gift of Dr T. Brunner from
University of Konstanz, Germany.
Cell Cultures
Human blood neutrophils were cultured at 1 × 106/ml in RPMI
1640 medium plus GlutaMAX (Invitrogen) supplemented with
5% FCS and antibiotics in the presence and absence of GM-CSF
(10 ng/ml), anti-FAS (1 μg/ml), TNF-α (50 ng/ml), Q-VD-Oph
(20 μM), PD169316 (10 μM), wortmannin (100 nM), DPI
(1 μM), GSK′872 (10 μM), GW806742X (5 μM), TPCK
(10 μM), GW311616A (1, 10, and 20 μM), AAPVCK (10 μM),
elastase inhibitor IV (10 μM) or the compounds 1–14 (the novel,
synthesized serine protease inhibitors at the indicated
concentrations). Pre-incubation with inhibitors and GM-CSF
stimulation before ligation of adhesion molecules were
performed for 30 min. Anti-CD44 (6 μg/ml) was added for
15 min prior to addition of GaM (20 μg/ml) for receptor
ligation. Cells were cultured for the indicated time periods.
Caspase-8-deficient Jurkat cells were cultured at 1 × 106/ml in
RPMI 1640 medium plus GlutaMAX (Invitrogen) supplemented
with 5% FCS and antibiotics in the presence and absence of
compound 1 (40 μM), compound 3 (20 μM), TNF-α (20 ng/ml),
Q-VD-Oph (20 μM), or the Smac mimetic AT-406 (100 nM).
Pre-incubation with compound 1 or compound 3 before
stimulation were performed for 30 min.
Determination of Cell Death
Cell death was assessed by uptake of 25 μΜ ethidium bromide
and flow cytometric analysis (FACSCalibur; BD Biosciences)
(Mihalache et al., 2011; Geering et al., 2011; Wang et al., 2016;
Amini et al., 2018). To determine whether cell death was
apoptosis, redistribution of phosphatidylserine (PS) in the
presence of propidium iodide (PI) was measured by flow
cytometry (Mihalache et al., 2011; Geering et al., 2011).
Oxidative Burst Measurements
Neutrophils were cultured as indicated and subsequently incubated
with 1 μMDHR at 37 °C for 30 min, placed on ice, and analyzed by
flow cytometry (Mihalache et al., 2011; Geering et al., 2011).
Immunoblotting
Immunoblotting experiments were performed as previously
described (Wang et al., 2016; Mihalache et al., 2011; Geering
and Simon, 2011). Briefly, human neutrophils were lyzed in
Triton lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM
Tris-HCl [pH 7.4], and 1 mM EDTA) containing both protease
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(protease inhibitor cocktail P8340 and PMSF; Sigma-Aldrich)
and phosphatase inhibitors (1 μM okadaic acid, 1 mM
Na3VO4, and 5 mM NaF). The lysates were heated at 95 °C
for 5 min. Proteins were separated by SDS-PAGE and
electroblotted onto polyvinylidene difluoride membranes
(Immobilion-P; Millipore, Bedford, MA). The membranes
were routinely blocked in TBS containing 0.1% Tween-20
and 5% nonfat dry milk, followed by incubation overnight
with the indicated Abs at 4 °C. The next morning, samples
were further incubated with the appropriate HRP-
conjugated secondary Ab for 1 h at room temperature.
Filters were developed using an ECL technique (ECL-Kit;
GE Healthcare) according to the manufacturer’s
instructions.
Human Neutrophil Elastase Activity Assay
Measurement of HNE activity on the supernatant of resting or
activated human neutrophils was performed by using a Abz-
APEEIMRRQ-EDDnp fluorescence resonance energy transfer
(FRET) substrate (Korkmaz et al., 2008). 150 μL of
neutrophils (2 × 105 cells) were cultured as indicated in RPMI
1640 medium and subsequently centrifuged at 2,000 RPM for
4 min at room temperature. The supernatants were then collected
and transtered in a white polypropylene-well, 96-well microplate.
Reactions were started by adding Abz-APEEIMRRQ-EDDnp to a
final concentration of 20 µM in a final reaction volume of 150 µL.
Fluorescent activity was immediately measured at 320 nm
excitation/420 nm emission using a spectrofluorometer
(SpectraMax M2; Molecular Devices, Biberach an der Riß,
Germany) as described previously (Korkmaz et al., 2008).
Relative fluorescence was obtained after subtraction of the
corresponding fluorescence of medium without cells at the
corresponding time point and subsequent norming of
the values to initially measured fluorescence.
Statistics
Data are presented as means ± SEM. One-way ANOVA followed
by a Tukey multiple comparison test was applied. A p value < 0.05
was considered statistically significant.
RESULTS
Chemical Characterization of a Series of
Novel Serine Protease Inhibitors
The general structure of all 14 compounds (Supplementary
Table S1) consists of the highly hydrophobic and relatively
rigid 2-naphthohydrazide or naphthalene-2-sulfonohydrazide
moiety, with meta or para substituted benzyl or
piperidinomethyl group on N′. The main difference between
the compounds is in the functional group on the phenyl or
piperidine ring that defines the acido-basic properties of
compounds. In the cytoprotective compounds 1 and 3, a
slightly basic amidoxime is present on para position of a
benzyl group. Compound 1 has an additional six membered
ring attached through carbonyl group, making it larger in size
compared to compound 3 (Supplementary Table S1).
Differential Effects of Serine Protease
Inhibitors on Spontaneous Neutrophil Death
in vitro
There is growing evidence for a role for serine proteases in the
regulation of neutrophil death (Conus and Simon, 2008; Loison
et al., 2014a; Loison et al., 2014b; Baumann et al., 2013; Benarafa
and Simon, 2017). To obtain further insight into this
involvement, we tested the effect of 14 potential serine
protease inhibitors on neutrophil death. Neutrophils, isolated
from peripheral blood of healthy donors, are known to undergo
apoptosis in vitro, a process called spontaneous or constitutive
apoptosis (Simon, 2003; Benarafa and Simon, 2017). Using this
in vitro system, we treated neutrophils with the compounds in a
concentration-dependent manner and measured viability after
24 h (Supplementary Figure S1). As a control, GM-CSF was used
to delay spontaneous neutrophil apoptosis (Dibbert et al., 1999;
Saba et al., 2002; Simon, 2003). Anti-FAS antibody and TNF-α,
both known as triggers of neutrophil apoptosis (Geering and
Simon, 2011; Geering et al., 2011), were applied as additional
controls. Approximately 40% of the untreated neutrophils
underwent cell death, which is referred as spontaneous
neutrophil apoptosis. Compounds 1 and 3 inhibited
spontaneous neutrophil death with similar efficacy as GM-CSF
and increased the average neutrophil survival at optimal
concentrations by approximately 20% (Supplementary Figure
S1). To determine the optimal inhibitory concentration, we
performed concentration-dependent experiments using
compound 1 at concentrations ranging from 1 to 75 µM and
compound 3 ranging from 1 to 30 µM. These experiments
confirmed the anti-death activity of both compounds. Optimal
inhibition of neutrophil death was achieved with 40 µM
compound 1 and 20 µM compound 3 (Supplementary Figure
S2). Taken together, these data suggest that compounds 1 and 3
target serine proteases involved in spontaneous apoptosis.
Therefore, we subsequently investigated the effects of both
compounds on different neutrophil death pathways.
Compounds 1 and 3 Block Spontaneous
Neutrophil Apoptosis, but Not
FAS-Mediated Apoptosis
Phosphatidylserine (PS) is normally confined to the inner plasma
membrane leaflet. However, PS appears on the external leaflet in
apoptotic cells. Although it has been shown that PS can be
externalized on the surface of cells undergoing other forms of
cell death including necroptosis (Gong et al., 2017; Oberst et al.,
2017; D’Cruz et al., 2018; Speir et al., 2020), the redistribution of
PS is still considered to be a feature of apoptotic cells and can be
detected by Annexin V binding to exposed PS. Moreover, it has
been demonstrated that the type of both spontaneous and FAS-
triggered neutrophil death is apoptosis (Simon, 2003). To
investigate whether compounds 1 and 3 decrease spontaneous
neutrophil death by inhibition of apoptosis, neutrophils were
analyzed by Annexin V/propidium iodide (PI) assay. Compounds
1 and 3 decreased the percentage of apoptotic neutrophils
(Annexin V+/PI−) in untreated neutrophils (Supplementary
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Figure S3A). In contrast, FAS-induced apoptosis was not blocked
by either compounds 1 or 3 (Supplementary Figure S3A). In
contrast, the pan-caspase inhibitor Q-VD-Oph prevented FAS-
induced death (Supplementary Figure S3B).
Caspase-3 is an effector caspase and its activation is crucial for
FAS-mediated neutrophil apoptosis (Simon, 2003). In agreement with
previously published work, we observed caspase-3 cleavage after 8 h
treatment with anti-FAS antibody, suggesting caspase-3 activation as a
consequence of FAS ligation (Supplementary Figure S3C) (Geering
et al., 2011; Mihalache et al., 2011; Wang et al., 2016). While Q-VD-
Oph prevented caspase-3 cleavage, neither compounds 1 and 3 had
any effect (Supplementary Figure S3C, left panel). Compounds 1 and
3 had also no effect on cleaved caspase-3 in the absence of FAS
activation (Supplementary Figure S3C, right panel). Taken together,
though both compounds were able to block spontaneous apoptosis,
we obtained no evidence for an involvement of serine proteases in FAS
receptor-mediated apoptosis in our system.




It has been previously shown that multiple triggers can induce a
non-apoptotic death in cytokine-primed neutrophils which uses
components of a death pathway called necroptosis (von Gunten
et al., 2005; Mihalache et al., 2011; Wehrli et al., 2014; Wang et al.,
2016; Wang et al., 2018). In neutrophils, this pathway results in
the activation of the NADPH oxidase, resulting in the production of
high levels of ROS. Pharmacological or genetic inactivation of the
NADPH oxidase prevents this non-apoptotic neutrophil death (von
Gunten et al., 2005; Mihalache et al., 2011;Wehrli et al., 2014; Wang
et al., 2016; Wang et al., 2018). In this study, we used the death
triggered by CD44 ligation, a system which has been well
characterized previously (Mihalache et al., 2011; Wang et al., 2016).
In agreement with the previously published work (Mihalache
et al., 2011; Wang et al., 2016), CD44-mediated cell death in GM-
CSF-primed neutrophils (Figure 1A). Both compounds 1 and 3
inhibited CD44-triggered neutrophil necroptosis in a concentration-
dependent manner. Optimal inhibition of neutrophil necroptosis
was achieved with 40 µM compound 1 and 20 µM compound 3
(Figure 1A). We next analyzed ROS production following CD44
ligation of GM-CSF-primed neutrophils. Pharmacological inhibition
of RIPK3 (GSK′872), MLKL (GW806742X), p38 MAPK
(PD169316), PI3K (wortmannin), or NADPH oxidase (DPI)
blocked ROS production as described previously (Wang et al.,
2016). Both compounds 1 (40 μM) and 3 (20 μM) also strongly
reduced ROS production induced in this death pathway (Figure 1B),
suggesting that serine protease(s) are involved proximal to NADPH
oxidase activation.
Serine Protease Activity Is Required for
MLKL Phosphorylation as Well as
Subsequent p38 MAPK and PI3K Activation
for CD44-Triggered Neutrophil Necroptosis
To gain insight into the signaling events leading to the block in
ROS formation, we next addressed whether serine protease
FIGURE 1 | CD44-induced ROS production and subsequent necroptosis in GM-CSF-primed neutrophils require serine protease activity. (A) Concentration-
dependent effect of serine protease inhibitors, compounds 1 or 3, on CD44-triggered necroptosis in GM-CSF-primed neutrophils. GM-CSF-primed neutrophils were
precultured in the presence and absence of compound 1 (10, 20, or 40 μM) or compound 3 (10, 20, or 40 μM), and subsequently stimulated with anti-CD44 mAb for
24 h. Cell death was assessed by uptake of 25 μM ethidium bromide with flow cytometric analysis. (B) DHR oxidation assay. GM-CSF-primed neutrophils were
precultured in the presence and absence of the serine protease inhibitor compounds 1 (40 μM) or 3 (20 μM), the RIPK3 inhibitors GSK′872 (10 μM), the MLKL inhibitors
GW806742X (5 μM), the p38 inhibitor PD169316 (10 μM), the PI3K inhibitor wortmannin (100 nM), or the NADPH oxidase inhibitor DPI (1 μM) and subsequently
stimulated with anti-CD44mAb for 15 min before measured by flow cytometry. All values are means ± SEM of at least 3 independent experiments. *p < 0.05, **p < 0.01,
***p < 0.001.
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inhibition by compounds 1 and 3 modulates the phosphorylation
of MLKL, p38 MAPK and AKT, signaling events known to be
proximal to ROS production in CD44-triggered neutrophil
necroptosis (Wang et al., 2016).
CD44 ligation in GM-CSF-primed neutrophils induced the
phosphorylation of MLKL as previously described (Wang et al.,
2016), a signaling event which is inhibited by compound 1 or
compound 3 (Figure 2A). However, the inhibition effect of
compound 3 on MLKL seems less efficient compared to
compound 1 (Figure 2A). To further investigate whether these
two compounds can indeed significantly inhibit MLKL activity,
we also analyzed the p-MLKL expression levels quantified to the
control condition of MLKL. The results showed that both
compounds 1 and 3 significantly inhibit MLKL activity in
CD44-induced cell death system (Figure 2A). GSK′872, an
inhibitor of RIPK3, is able to abrogate MLKL phosphorylation
(Figure 2B), confirming that MLKL is indeed phosphorylated in
a RIPK3-dependent manner in this system. Furthermore, we
found that both compounds 1 and 3 can inhibit p38 MAPK
and AKT phosphorylation (Figure 2A and C). Moreover, the
inhibitors alone had no effect on the expression and
phosphorylation of MLKL, p38 MAPK or AKT (Figure 2D).
In addition, neither compound interacted directly with the
RIPK3-MLKL complex, since they were not able to block
necroptosis induced by combinatorial treatment with TNF-α, the
Smac mimetic AT-406, and Q-VD-Oph in caspase-8-deficient
FIGURE 2 | Serine protease activity is required for RIPK3-dependent MLKL phosphorylation, and subsequent p38 MAPK and PI3K activation in CD44-induced
necroptosis in GM-CSF-primed neutrophils. (A–C and E–G) Immunoblotting. Neutrophils were cultured as indicated and subsequently stimulated with anti-CD44 mAb
for 5 min. (D) Immunoblotting. Neutrophils were cultured in the presence and absence of compound 1 (40 μM) or compound 3 (20 μM) for 1 h. Cell lysates were analyzed
by immunoblotting for phosphorylated MLKL, phosphorylated AKT, and phosphorylated p38 MAPK. MLKL, AKT, p38, and GAPDH expression levels were
analyzed as loading controls. Representative immunoblots are shown (n ≥ 3). (A) Upper panel: p-MLKL protein expression levels were quantified relative to the control
condition of MLKL. Data are from 3 independent experiments. **p < 0.01, ***p < 0.001.
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 6149286
Wang et al. Serine Protease Activity in Neutrophil Death
Jurkat cells (Supplementary Figure S4) (Laukens et al., 2011; Amini
et al., 2016).
These data imply that serine protease activity is involved in
signaling events proximal to NADPH oxidase activation. We
used TPCK, a broad-spectrum pharmacological serine
protease inhibitor, to block MLKL, p38 MAPK and AKT
activities. Indeed, TPCK completely blocked their
phosphorylation (Figure 2E–2G). TPCK also blocked
CD44-induced ROS production and subsequent necroptosis
in GM-CSF-primed neutrophils (Supplementary Figure S5).
Taken together, a serine protease activity is required for ROS
production by activating MLKL, p38 MAPK or AKT
phosphorylation events following CD44 ligation in GM-
CSF-primed neutrophils. However, the responsible serine
protease(s) remain(s) to be identified.
Possible Serine Proteases Involved in
CD44-Induced ROS and Cell Death
We next tested if compounds 1 and 3 were able to inhibit the
serine proteases human neutrophil elastase (HNE), cathepsin G
(CatG), and proteinase 3 (PR3) that are known to be present in
azurophilic granules of neutrophils (Benarafa and Simon, 2017).
The enzymes trypsin and α-chymotrypsin as well the inhibitors
Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK)
and TPCK served as controls. Compound 1, at 25 or 50 μM
concentration, was able to inhibit 63% or 74% of HNE activity,
respectively (Figure 3). At 50 μMconcentration, compound 1 can
inhibit 52% of CatG activity (Figure 3). In contrast, compound 1
was unable to inhibit PR3, trypsin or α-chymotrypsin activities
(Figure 3). Compound 3, at 25 or 50 μM concentration, was able
to inhibit 49% or 68% of HNE activity, respectively (Figure 3). In
contrast, compound 3 did not inhibit CatG, PR3, and trypsin
activities (Figure 3). However, at 25 and 50 μM, compound 3 was
able to inhibit α-chymotrypsin activity (Figure 3). Looking at the
structure-activity relationship, the main difference between
compound 1 and 3 is in the additional piperidine ring present
in compound 1 but not 3. This suggests that the selectivity toward
CatG and α-chymotrypsin is a result of the presence or absence of
the piperidine ring. On the other hand, both compound 1 and 3
inhibited at high concentrations partially the enzymatic activity of
HNE, pointing to a possible proximal role of HNE in the RIPK3-
MLKL – mediated necroptotic death pathway in neutrophils.
We next investigated the HNE activity in the supernatants of
GM-CSF-primed and CD44-activated neutrophils. Our results
provided evidence that HNE is activated in the process of
neutrophil activation, but an increased enzymatic activity did
not occur before 30 min (Figure 4A). On the other hand,
maximal ROS levels are seen at 15 min in GM-CSF-primed
and CD44-activated neutrophils (Mihalache et al., 2011),
suggesting that increased HNE activity is rather a late event.
To further exclude that HNE activity is required to activate the
RIPK3-MLKL – mediated necroptotic death in neutrophils, we
tested if GW311616A and two additional well known HNE
inhibitors are able to block the pathway. All three HNE
inhibitors did not prevent the phosphorylation of MLKL and
p38 (Figure 4B), ROS production (Figure 4C) and cell death
(Figure 4D) in GM-CSF-primed and CD44-activated
neutrophils. Therefore, it is unlikely that HNE is the proximal
serine protease required to activate the RIPK3-MLKL pathway
following death triggering. It should be noted that fibroblast
activation protein-α (FAP-α), another serine protease
expressed in neutrophils, acts in parallel to the RIPK3-MLKL
pathway and is not able to activate it in the process of CD44-
mediated neutrophil death (Wang et al., 2020).
DISCUSSION
Two novel serine protease inhibitors, compounds 1 and 3, can
block CD44-triggered necroptosis in GM-CSF-primed human
neutrophils by blocking RIPK3-MLKL, p38 MAPK, PI3K, and
NADPH oxidase activation. In contrast to classical necroptosis
FIGURE 3 | Comparative activity of compounds against five different
serine proteases. Compound 1, 3, TPCK, and TLCK were incubated with
trypsin (Try), α-chymotrypsin (α-Chy), human neutrophil elastase (HNE),
cathepsin G (CatG), and proteinase 3 (PR3) at 37 °C for 30 min.
Subsequently, reactions were started by adding an enzyme-specific
substrate. Substrate hydrolysis was monitored in a kinetic mode for 60 min.
The initial rates of reactions were used to calculate the % relative inhibition of
the enzymes. Results are presented as mean ± SEM of 3 independent
experiments, run in duplicate. (A) Relative inhibition (%) of serine proteases for
10 µM compound 1, 3, TPCK, and TLCK. (B) Relative inhibition (%) of serine
proteases for 25 µM compound 1, 3, TPCK, and TLCK. (C) Relative inhibition
(%) of serine proteases for 50 µM compound 1, 3, TPCK, and TLCK.
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 6149287
Wang et al. Serine Protease Activity in Neutrophil Death
(Chen et al., 2014; Dondelinger et al., 2014; Quarato et al., 2016;
Zhao et al., 2016; Petrie et al., 2017), it seems that MLKL is here
not involved in a pore-forming mechanism within the plasma
membrane (Wang et al., 2016). In this cell death pathway present
in human neutrophils, it rather acts within a signaling cascade
leading to p38 mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3′-kinase (PI3K) activation, followed by the
production of high levels of reactive oxygen species (ROS), most
likely owing to nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activation (Wang et al., 2016). It should be
noted, however, that in mouse neutrophils, classical necroptosis
can be triggered by the SMAC-mimetic birinapant in
combination with the pan-caspase inhibitor z-VAD-fmk
whereby MLKL accumulates in the cell membrane (D’Cruz
et al., 2018).
Our findings imply that a serine protease activity is required
proximal of RIPK3-MLKL, p38 MAPK, PI3K, and NADPH
oxidase activation. On the other hand, RIPK3 has been shown
to activate the NLRP3 inflammasome, leading to IL-1β
inflammatory responses (Lawlor et al., 2015; Weinlich et al.,
2017). Therefore, there is a possibility that a RIPK3-NLRP3
inflammasome-dependent pathway is activated in human
neutrophils following GM-CSF priming and adhesion receptor
activation. Whether compounds 1 and 3 could additionally block
RIPK3-dependent inflammation in neutrophil-associated
diseases (Shi et al., 2015; Weinlich et al., 2017; Wang et al.,
2018; Frank and Vince, 2019; Broz et al., 2020) remains unclear
and requires additional experimentation.
We used a pharmacological approach to understand a non-
apoptotic death pathway in human neutrophils. Such an
FIGURE 4 | Pharmacological inactivation of HNE does not block CD44 death signaling in GM-CSF-primed neutrophils. (A) Enzymatic assay. Supernatant HNE
activity can be measured upon CD44 activation in GM-CSF-primed neutrophils. Data are representative of 3 independent experiments. (B) Immunoblotting. Neutrophils
were cultured as indicated and subsequently stimulated with anti-CD44 mAb for 5 min. Preincubation with GW311616A (10 μM), AAPVCK (10 μM), or elastase inhibitor
IV (10 μM) was performed for 30 min. Cell lysates were analyzed by immunoblotting for phosphorylated MLKL and phosphorylated p38 MAPK. MLKL, p38 and
GAPDH expression levels were analyzed as loading controls. (C) DHR oxidation assay. GM-CSF-primed neutrophils were precultured in the presence and absence of
GW311616A (1, 10, and 20 μM), AAPVCK (10 μM), or elastase inhibitor IV (10 μM), and subsequently stimulated with anti-CD44 mAb for 15 min before measured by
flow cytometry. DPI (1 μM) served as a control. (D) Viability assay. GM-CSF-primed neutrophils were precultured in the presence and absence of GW311616A (1, 10,
and 20 μM), AAPVCK (10 μM), or elastase inhibitor IV (10 μM) for 30 min and subsequently stimulated with anti-CD44 mAb for 24 h. Cell death was assessed by uptake
of 25 μM ethidium bromide with flow cytometric analysis. All values are means ± SEM of at least 3 independent experiments. ***p < 0.001.
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approach has obvious limitations because pharmacological
inhibitors can have pleiotropic effects. Compounds 1 and 3
might be able to block serine proteases present in azurophilic
granules, which can also be involved, besides mitochondria, in
death processes of neutrophils (Conus et al., 2008). However, we
obtained no evidence that the compounds 1 and 3 would indeed
target either of the granule serine proteases HNE, CatG or PR3
within human neutrophils. Therefore, the identification of the
putative serine protease, which acts proximal to the RIPK3-
MLKL complex in these cells, remains to be identified. In spite
of this open question, our data suggest that serine proteases could
represent potential therapeutic targets in neutrophil-associated
disorders. Being able to prevent necroptotic-like neutrophil lysis,
compounds 1 and 3 might be suitable candidates to treat such
inflammatory diseases. Moreover, their chemical structures
should provide additional hints for drug design and development.
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